OncLive SOSS

Authors

Hiroji Iwata, MD, PhD

Latest:

Dr. Iwata on Final OS Results From the Phase 3 IMpassion130 Trial in TNBC

Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival results from the phase 3 IMpassion130 trial in triple-negative breast cancer.

Hirva Mamdani, MD

Latest:

Dr. Mamdani on Evaluating the Immunogenicity of STK11/TP53 Co-Mutations in NSCLC

Hirva Mamdani, MD, discusses the rationale to evaluate the immunogenicity of STK11 and TP53 co-mutations in non–small cell lung cancer.

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS

Latest:

Dr. Mehanna on the Design of the De-ESCALaTE Trial in HPV+ Head and Neck Cancer

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery, director, Institute of Head and Neck Studies and Education at the Institute of Cancer and Genomic Sciences, University of Birmingham, discusses the design of the De-ESCALaTE trial in patients with HPV-positive head and neck cancer.

Holger L. Gieschen, MD

Latest:

Dr. Gieschen on Toxicities Associated With Radiation Therapy in Prostate Cancer

Holger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the toxicities associated with radiation therapy in prostate cancer.

Holli Dilks, PhD

Latest:

Challenges With a Precision Medicine-Based Approach in Oncology

Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

Hollings Cancer Center

Latest:

New Discovery Enhances Understanding of Colorectal Cancer

MUSC Hollings Cancer Center researchers discovered a novel mechanism showing how a certain gene mutation can allow tumors to evade detection by the immune system in colorectal cancer patients.

Holly G. Prigerson, PhD

Latest:

Holly Prigerson on Chemotherapy Regimens for Patients With Advanced Gastric Cancer

Holly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.

Latest:

Dr Rugo on the FDA Approval of Inavolisib Plus Palbociclib and Fulvestrant in PIK3CA-Mutated HR+/HER2– Breast Cancer

Hope S. Rugo, MD, discusses the FDA approval of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutated, HR+/HER2– metastatic breast cancer.

Hope S. Rugo, MD

Hope S. Rugo, MD, is the Director of the Women's Cancers Program, the Division Chief of Breast Medical Oncology, and a Professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center. She is also a Professor Emeritus at UCSF

Latest:

Dr Rugo on Elacestrant-Based Combos in ER+/HER2– Locally Advanced or Metastatic Breast Cancer

Hope S. Rugo, MD, discusses an open-label umbrella study evaluating elacestrant in combination with everolimus or abemaciclib in ER-positive/HER2-negative advanced breast cancer.

Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center

Latest:

Guideline Recommendations for CIN Prophylaxis

Current recommendations by the National Comprehensive Cancer Network on chemotherapy-induced neutropenia prophylaxis, with special considerations for managing patients with cancer during COVID-19.

Hope S. Rugo, MD, Her UCSF Comprehensive Cancer Center

Hope S. Rugo, MD, UC

Hope S. Rugo, MD, UCSF

Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center

Latest:

Therapeutic Advances in Prophylaxis Against CIN

An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.

Hope S. Rugo, MD, University of California

Hope S. Rugo, MD, University of California San Francisco Helen Diller Family Comprehensive Cancer Center

Hope S. Rugo, MD, University of CaliforniaChristy A. Russell, MD, University of Southern California

Hospital of the University of Pennsylvania

Hossein Borghaei, DO

Latest:

Lurbinectedin + Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Results of the Phase 3 IMforte Trial

The Phase 3 IMforte trial demonstrated that maintenance therapy with lurbinectedin plus atezolizumab was well tolerated and explored a novel approach to extending disease control following first-line treatment in patients with extensive-stage small cell lung cancer.